Wall Street brokerages predict that Neuronetics Inc (NASDAQ:STIM) will post ($0.43) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Neuronetics’ earnings. Neuronetics posted earnings of ($30.60) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 98.6%. The business is scheduled to issue its next earnings report before the market opens on Tuesday, August 6th.
According to Zacks, analysts expect that Neuronetics will report full-year earnings of ($1.65) per share for the current financial year, with EPS estimates ranging from ($1.67) to ($1.62). For the next year, analysts forecast that the firm will post earnings of ($1.58) per share, with EPS estimates ranging from ($1.74) to ($1.41). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow Neuronetics.
Neuronetics (NASDAQ:STIM) last announced its earnings results on Tuesday, May 7th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.05). Neuronetics had a negative return on equity of 1,385.60% and a negative net margin of 47.21%. The business had revenue of $12.73 million for the quarter, compared to analyst estimates of $12.72 million.
Several equities research analysts have recently weighed in on STIM shares. Zacks Investment Research downgraded shares of Haynes International from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. ValuEngine upgraded shares of Zogenix from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 27th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $31.60.
In related news, insider Daniel Guthrie sold 3,685 shares of the stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $14.53, for a total transaction of $53,543.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Peter Donato sold 23,053 shares of the stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $15.27, for a total transaction of $352,019.31. The disclosure for this sale can be found here. Insiders have sold 35,333 shares of company stock valued at $533,886 over the last three months. 12.00% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of STIM. Advisor Group Inc. purchased a new position in Neuronetics during the fourth quarter worth about $27,000. BNP Paribas Arbitrage SA purchased a new position in Neuronetics during the first quarter worth about $41,000. Bank of America Corp DE raised its holdings in Neuronetics by 967.7% during the fourth quarter. Bank of America Corp DE now owns 5,787 shares of the company’s stock worth $111,000 after purchasing an additional 5,245 shares in the last quarter. New York State Common Retirement Fund purchased a new position in Neuronetics during the fourth quarter worth about $122,000. Finally, Rhumbline Advisers purchased a new position in Neuronetics in the first quarter valued at about $204,000. 81.03% of the stock is owned by hedge funds and other institutional investors.
Shares of STIM traded down $0.19 during mid-day trading on Friday, hitting $11.24. 101 shares of the company’s stock were exchanged, compared to its average volume of 76,209. Neuronetics has a fifty-two week low of $8.90 and a fifty-two week high of $39.39. The stock has a market cap of $204.14 million and a price-to-earnings ratio of -4.25. The company has a 50 day simple moving average of $11.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 8.94 and a quick ratio of 8.74.
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.